Biological Medicinal Products: Classification, Development and Pharmacovigilance

Purpose and Scope

Biological medicinal products form a diverse group of medicines whose active substances are produced by or derived from biological sources. They include products as different as recombinant proteins, monoclonal antibodies, immunological medicinal products, medicines derived from human blood or plasma, and advanced therapy medicinal products. The common feature is not a single therapeutic mechanism or molecular structure, but the biological origin of the substance and the consequent need to consider the production process together with physicochemical and biological methods when characterising the product.

This distinction matters for pharmacovigilance because a biological medicinal product cannot always be understood from its active substance name alone. The characteristics of the molecule or biological material may depend on the source, expression system, manufacturing process, purification, formulation and controls applied throughout production. Biological medicines can also exhibit inherent variability, and changes introduced during manufacture may affect product characteristics without changing the name under which the product is supplied. EMA therefore gives product and batch traceability particular importance in the pharmacovigilance of biological medicines. [1]

The purpose of this article is to establish the conceptual framework for the QPPV.com Product Pharmacovigilance series. It first defines the biological medicinal product in the EU regulatory context, then explains the main ways biological products can be classified and why those classifications overlap. It subsequently connects the product taxonomy to development, manufacturing, immunogenicity, traceability and pharmacovigilance. Detailed treatment of individual product families, such as vaccines, monoclonal antibodies, plasma-derived products, biosimilars and advanced therapies, is reserved for later articles in the series.

The article is therefore a framework rather than a catalogue of products. Its role is to give the reader a consistent map that can be used to understand why different biological product families require different safety considerations while remaining within the same overarching pharmacovigilance system.

What Is a Biological Medicinal Product?

The EU legal definition begins with the concept of a biological substance. Part I of Annex I to Directive 2001/83/EC describes a biological substance as one produced by or extracted from a biological source and requiring, for its characterisation and determination of quality, a combination of physicochemical-biological testing together with the production process and its control. A biological medicinal product is a medicinal product containing such a biological substance. [2]

This definition is deliberately broader than the everyday use of terms such as "biologic" or "biological drug". It does not restrict biological medicinal products to proteins, to biotechnology-derived medicines, or to products made from living cells. The EU framework encompasses several distinct groups, and the scientific characteristics that make one product biological may be quite different from those that define another.

EMA's biosimilar guidance illustrates the breadth of the category by identifying recombinant proteins, monoclonal antibodies, medicinal products derived from human blood and plasma, immunological medicinal products and advanced therapy medicinal products as examples of biological medicinal products. [3] This breadth is essential to the taxonomy used in this series: biological medicinal product is an umbrella category, not a single product class with one common molecular architecture.

The distinction from chemically synthesised medicines is therefore not simply that biological medicines are "larger" or "more complicated". Some biological active substances are relatively small proteins, while others are highly complex molecules or living cellular products. What matters regulatory and scientifically is the nature and origin of the active substance and the extent to which its relevant characteristics depend on biological systems and the manufacturing process.

Why the Definition Matters for Pharmacovigilance

The regulatory definition leads directly to a pharmacovigilance consequence. If the characteristics of a biological active substance are linked to both the substance itself and the process by which it is produced, then safety surveillance must be able to distinguish the product sufficiently to identify product-specific safety information.

This is particularly important when several biological medicines contain related active substances or are used for the same clinical purpose. Two products may share an international non-proprietary name or belong to the same therapeutic class while still requiring product-level identification during pharmacovigilance. For biological medicines, product-specific concerns may include immunogenicity, manufacturing-related changes, batch-specific issues or differences in biological characteristics. EMA's product-specific GVP guidance consequently states that continuous product and batch traceability in clinical use is a key requirement for biologicals. [1]

The implication is not that every adverse reaction to a biological medicine is caused by manufacturing variability. Rather, the pharmacovigilance system must preserve enough information to determine whether a safety concern is associated with the product, a related product, a particular batch, a change in manufacture, or the biological substance or mechanism more generally.

This is why biological-product pharmacovigilance begins with product identity and classification. Before a safety signal can be interpreted at the appropriate level, the system needs to know what product was actually administered and how that product relates to other products in the same biological or therapeutic landscape.

Biological Medicinal Products as an Umbrella Category

A useful starting point is to separate three concepts that are often treated as though they were equivalent:

1. Biological medicinal product — the broad regulatory category based on the nature and origin of the biological substance.
2. Product family or modality — a scientifically meaningful grouping such as monoclonal antibodies, recombinant proteins, vaccines or cell-based therapies.
3. Individual medicinal product — the specific authorised product with its own product identity, manufacturing process, formulation, indications, safety evidence and regulatory history.

These levels answer different questions. The first asks whether the medicine belongs to the biological category. The second asks what type of biological medicine it is and which scientific characteristics it shares with related products. The third asks what is known about one particular product.

The distinction becomes especially important for pharmacovigilance. A class-level mechanism may explain why several products could plausibly produce similar adverse reactions, but it does not establish that a safety issue is a class effect. Conversely, a product-specific manufacturing change or immunogenicity concern may not apply to other products in the same family. The pharmacovigilance assessment must therefore operate at the level supported by the evidence.

The Product Pharmacovigilance series will use these levels deliberately. The biological-landscape articles establish the overall taxonomy; type and subtype articles explain the scientific and regulatory characteristics of each family; individual-product articles then examine product-specific development and safety evidence without repeating the entire class discussion.

The Main Dimensions Used to Classify Biological Medicines

There is no single classification axis that is sufficient for all pharmacovigilance purposes. Biological medicinal products can be grouped according to their biological source, molecular or cellular composition, production technology, mechanism of action, therapeutic use, regulatory category or manufacturing characteristics. These dimensions overlap rather than forming one simple hierarchy.

For example, monoclonal antibodies can be grouped together because of their molecular architecture and method of production, while also being subdivided according to target, antibody format or engineering characteristics. Vaccines can be classified according to the nature of the antigen and platform used to generate the immune response. Advanced therapy medicinal products are defined through specific legal categories based on genes, cells and tissue engineering. Plasma-derived products are distinguished by their biological source and manufacturing pathway.

For QPPV.com, the most useful taxonomy is therefore a layered classification. It should first establish the broad biological landscape, then identify scientifically and regulatorily meaningful families, and finally identify subtypes where the pharmacovigilance implications differ materially.

A simplified representation is:

This layered approach avoids a common error: treating regulatory categories, scientific modalities and therapeutic classes as though they were interchangeable. They are not. A product may simultaneously belong to several useful categories, and each category may be relevant to a different pharmacovigilance question.

Regulatory Framework

The EU regulatory framework for biological medicinal products is distributed across several instruments rather than contained in one biological-medicines regulation. Directive 2001/83/EC provides core definitions and requirements for medicinal products, including the biological medicinal product definition in Annex I. Regulation (EC) No 726/2004 establishes the centralised procedure and includes important categories of biotechnology-derived medicinal products within the mandatory scope of that procedure. Advanced therapy medicinal products are governed by Regulation (EC) No 1394/2007 in conjunction with the relevant provisions of Directive 2001/83/EC. [2,4,5]

The pharmacovigilance framework is provided by the EU pharmacovigilance legislation and the EMA's Good Pharmacovigilance Practices. EMA currently identifies biological medicinal products as one of the product- or population-specific GVP considerations, alongside areas such as vaccines and paediatric medicines. [6] The biological-products guidance adds product-specific considerations to the general pharmacovigilance framework rather than replacing it.

This distinction is important operationally. The general GVP modules establish the pharmacovigilance system, processes and responsibilities that apply across medicinal products. Product-specific guidance then explains where the characteristics of a particular product type require additional attention. Biological-product pharmacovigilance is therefore best understood as general GVP applied with additional controls and scientific considerations appropriate to biological medicines.

The regulatory framework also continues to evolve. EMA notes that GVP modules are periodically reviewed and that amendments to the underlying pharmacovigilance implementing legislation and new ICH guidelines can lead to further revisions. [6] Consequently, regulatory statements in this series should be anchored to the applicable legislation and current guidance rather than treated as permanently fixed descriptions of the EU system.

Development of Biological Medicinal Products

The classification of a biological medicinal product becomes more useful when it is connected to how the product is developed. For a chemically synthesised active substance, the identity and quality of the active substance can often be described primarily through its molecular structure and analytical specifications. For a biological product, the development programme must also establish that the biological substance produced through a defined process has the required identity, quality, biological activity, purity and consistency. The development strategy therefore links the product itself to the process used to make it.

This relationship does not mean that biological products are uncontrolled or inherently inconsistent. Modern analytical and manufacturing technologies allow extensive characterisation and control. The regulatory challenge is instead that the relevant quality attributes of a biological product may arise from a combination of molecular structure, higher-order structure, post-translational modifications, aggregation state, impurities, formulation and other process-dependent characteristics. The extent and type of these attributes vary between product families.

The development pathway consequently differs across the biological landscape. A recombinant therapeutic protein is developed around a defined biological expression system and a controlled manufacturing process. A monoclonal antibody requires additional consideration of antibody structure, glycosylation and biological functions. A plasma-derived product begins with human plasma as a biological starting material and requires controls appropriate to collection, pooling, pathogen safety and purification. A cell or gene therapy introduces further considerations because the medicinal product may contain living cells or genetic material and its characteristics may depend on biological behaviour after administration. These distinctions justify separate type-level articles later in the series rather than attempting to treat all biological products as one scientific class.

Development Evidence and the Product Definition

For pharmacovigilance purposes, the development programme establishes the baseline against which later safety information is interpreted. Preclinical studies, pharmacology, toxicology, clinical trials, immunogenicity assessments, manufacturing development and product characterisation together define what is known about the product before wider clinical use.

The evidence is therefore not limited to clinical adverse-event data. Information about the biological activity of the product, its mechanism, impurities, formulation and manufacturing process can provide context for understanding an adverse reaction or a potential signal. This is particularly relevant when a safety observation has a plausible relationship to immunological activity, altered product characteristics or a manufacturing change.

The same principle applies to changes made after initial development. A biological product may undergo process changes during its lifecycle, for example to improve manufacturing capacity, introduce a new facility, change a raw material, modify purification or otherwise improve the process. Such changes are assessed through the applicable quality and regulatory comparability framework. Pharmacovigilance does not replace that assessment, but it provides an important post-authorisation source of evidence about whether the product's safety profile remains consistent with the established understanding.

Manufacturing Process as Part of the Product's Quality Profile

The relationship between a biological active substance and its manufacturing process is one of the central concepts needed to understand biological-product pharmacovigilance. EMA's GVP guidance explains that biological active substances are complex and are generally produced using complex, manufacturer-specific processes. It identifies the manufacturing process, including elements such as the cell line, starting materials, fermentation and purification, as an important determinant of the resulting product's quality, safety and efficacy. [7]

The practical implication is that a pharmacovigilance system should not regard manufacturing information as belonging exclusively to quality assurance. Quality and pharmacovigilance answer different questions, but they may need to be connected when a safety concern could plausibly relate to product characteristics or a manufacturing change.

For example, a quality investigation may identify an unexpected change in a critical quality attribute. That finding does not automatically constitute a pharmacovigilance signal. Conversely, an emerging clinical pattern does not automatically demonstrate a manufacturing defect. The two processes become connected when evidence indicates that a product characteristic, manufacturing change or batch-related factor could help explain the clinical observation. Effective governance therefore requires appropriate interfaces between pharmacovigilance, quality, regulatory affairs, manufacturing and medical functions.

This is one reason the biological-product taxonomy should not be reduced to molecular categories. Two products with closely related active substances may have different manufacturing processes and therefore require separate product identification in safety surveillance. Conversely, products with very different structures may share a manufacturing-related pharmacovigilance principle. The relevant classification depends on the question being asked.

Product Lifecycle and Manufacturing Changes

A biological medicinal product should be understood as a lifecycle rather than as a fixed object created at the time of first authorisation. Development establishes an initial product and process; commercial manufacture may subsequently evolve; manufacturing sites and suppliers may change; analytical methods may become more capable; and new clinical experience may change the understanding of safety.

Regulatory comparability principles are intended to demonstrate that a manufacturing change does not adversely affect the quality, safety or efficacy of the product. The level of evidence required depends on the nature and extent of the change and on the ability of analytical, non-clinical and clinical data to establish comparability. [8]

Pharmacovigilance therefore has a complementary lifecycle role. It continues to monitor the product after a change has been introduced and may contribute real-world evidence that supports or challenges the existing safety understanding. This is not a requirement to attribute every post-change adverse event to the change. Rather, the purpose is to maintain the ability to detect and investigate meaningful differences in the safety profile over time.

A useful operational distinction is:

The important principle is that comparability and pharmacovigilance are complementary rather than interchangeable controls. Comparability is a prospective and regulatory assessment of the effect of a manufacturing change; pharmacovigilance is an ongoing process for detecting and evaluating safety information during clinical use.

Immunogenicity as a Product-Dependent Safety Consideration

The biological nature of many medicinal products creates another major connection between product development and pharmacovigilance: immunogenicity. Biological medicines can induce immune responses to the active substance or other product-related components. The clinical relevance of such responses varies considerably between products and may include changes in pharmacokinetics or pharmacodynamics, loss of efficacy, hypersensitivity or other immune-mediated effects.

Immunogenicity should not, however, be treated as a universal adverse effect of all biological medicines or as evidence of poor product quality. The immune response depends on the product, patient, disease, treatment context and exposure, as well as on characteristics of the molecule and its formulation. The regulatory and scientific assessment is therefore product-specific.

EMA's biological-product GVP guidance identifies immunogenicity as one of the specific pharmacovigilance challenges associated with biologicals and directs readers to the applicable scientific guidance on immunogenicity assessment. [7] The consequence for the QPPV.com taxonomy is that immunogenicity will be treated as a cross-cutting pharmacovigilance concept rather than as a defining feature of one single product family.

This distinction will become important in later articles. An immunogenicity discussion for a monoclonal antibody will differ from one for an enzyme replacement therapy, a coagulation factor or a cell therapy. The underlying concept is shared, but the biological mechanism, assays, clinical consequences and evidence requirements are not necessarily the same.

Why Product and Batch Traceability Matters

Once biological products are classified at the appropriate level, the next requirement is to preserve that identity during clinical use. EMA's GVP guidance states that continuous product and batch traceability is a key requirement for biological medicines. [1]

Traceability allows pharmacovigilance information to be connected to the product that was actually administered. This is particularly important where multiple products contain the same or closely related active substances, where reference products and biosimilars coexist, or where several presentations and manufacturing sites are involved.

Traceability should therefore be understood as more than an administrative field in a case-processing system. It creates the evidentiary link between an individual exposure and the medicinal product to which a safety observation may relate. Depending on the product and the safety question, relevant information can include product name, active substance, strength or presentation, manufacturer or marketing authorisation holder, batch or lot information and the circumstances of administration.

The purpose is not to imply that every safety signal will be batch-specific. Most safety assessments will require broader clinical, epidemiological and scientific evidence. Rather, traceability preserves an option that may become critical when a product-specific or batch-related hypothesis needs to be tested.

Reference Products, Biosimilars and Related Biological Products

The biological landscape also contains products that are scientifically related but have different regulatory histories. EMA's GVP guidance applies to reference biological products, biosimilars and related products, while recognising that specific considerations may differ according to the regulatory context. [7]

This creates an important distinction between similarity and identity. A biosimilar is developed to demonstrate similarity to a reference product through a comprehensive comparability exercise. That does not make the two medicinal products the same product for pharmacovigilance purposes. Each product has its own identity, manufacturing process and post-authorisation evidence.

The same principle applies to related biological products that contain the same or closely related active substance but are not authorised as biosimilars. Pharmacovigilance systems must therefore be capable of distinguishing products sufficiently to support case processing, signal detection and product-specific evaluation.

Detailed treatment of biosimilars, switching, interchangeability and product attribution is reserved for later articles in this series. At the landscape level, the essential point is that biological similarity does not remove the need for product-specific pharmacovigilance.

How the Classification Connects to Pharmacovigilance Practice

The classification established earlier in the article becomes operational when it determines what information needs to be captured, what scientific context is required for assessment and which specialist functions may need to interact.

At the broadest level, identifying a medicine as biological alerts the pharmacovigilance system to the applicability of the product-specific GVP considerations. The next level—product family—provides scientific context. Knowing that a product is a monoclonal antibody, vaccine, plasma-derived medicine or cell therapy points the assessor toward different mechanisms, safety characteristics and regulatory considerations. The subtype level becomes relevant when a technology or biological feature changes the expected safety profile or the way evidence should be interpreted. Finally, individual-product identification permits the assessment to be anchored to the actual medicine and, where appropriate, the batch.

This can be represented as a progression:

product identity → biological family → relevant subtype → mechanism and product characteristics → exposure and clinical evidence → signal assessment → regulatory action

The sequence is not a mandatory algorithm for every individual case. It is a conceptual model for maintaining the correct level of specificity. A pharmacovigilance professional should be able to move both down and up the hierarchy: from a reported product to its biological family when assessing plausibility, and from a class-level concern back to individual products when testing whether the evidence is product-specific or shared.

The same hierarchy will govern the remainder of the QPPV.com biological-product series. The next articles will progressively populate the product families and subtypes identified by this framework, while cross-cutting topics such as immunogenicity, traceability and lifecycle changes will be developed separately where they require deeper treatment.

How Biological Classification Shapes Pharmacovigilance Controls

The classification framework becomes meaningful only when it changes how pharmacovigilance information is interpreted and governed. The broad designation of a medicine as biological identifies a regulatory and scientific context, but it is usually the product family, subtype and individual product that determine which characteristics are relevant to a particular safety question. A pharmacovigilance system therefore needs enough granularity to preserve the identity of the product while retaining the ability to recognise shared mechanisms or class-level patterns.

This is particularly important for case processing and signal detection. A reported adverse reaction should be attributed to the medicinal product that was actually administered, rather than to a broad biological class merely because the products are related. At the same time, an assessor may need to consider whether the observed event is biologically plausible across a wider family of products. These are different analytical questions and should not be conflated.

The hierarchy established in this article provides a practical way to maintain that distinction:

The levels should inform one another without being substituted for one another. A class effect is an assessment conclusion supported by evidence; it is not created simply because several products share a biological modality. Likewise, a product-specific signal does not automatically imply a problem with the entire class.

Roles and Cross-Functional Interfaces

Biological-product pharmacovigilance frequently requires information that sits outside the pharmacovigilance department. The pharmacovigilance function remains responsible for its applicable safety activities, but effective assessment can depend on timely access to information held by quality, manufacturing, regulatory affairs, clinical development, medical functions and supply or distribution organisations.

The need for these interfaces follows directly from the characteristics described earlier in the article. If a safety observation could relate to a product characteristic, manufacturing change or batch, pharmacovigilance needs a controlled route for obtaining the relevant information. If a manufacturing investigation identifies information that may have safety implications, the organisation needs a route for bringing that information into the pharmacovigilance system. Neither function should assume that the other will automatically identify the issue.

The precise organisational arrangement is an operational matter rather than a universal regulatory structure. What matters is that responsibilities, escalation routes, decision rights and records are defined sufficiently to support timely and scientifically sound assessment.

A useful governance model is therefore based on interfaces rather than departmental ownership alone:

These interfaces should not be interpreted as a requirement for every organisation to establish identical committees or workflows. They are the practical consequence of the fact that biological-product safety information can cross traditional functional boundaries.

Evidence and Records Supporting Biological-Product Pharmacovigilance

The biological-product framework also affects the evidence that should be available to support pharmacovigilance decisions. The exact records depend on the product and process, but the system should be capable of connecting the safety assessment to the product identity, the relevant scientific evidence and the reasoning used to reach the conclusion.

For a product-specific concern, relevant evidence may include the case information, product and batch details where available, product information, known pharmacology, immunogenicity information, cumulative safety data, signal assessments and relevant quality or manufacturing information. For a broader concern, the evidence may additionally include data from related products, epidemiological information, literature, clinical studies, regulatory assessments and mechanistic evidence.

The purpose of maintaining these records is not merely to demonstrate that a task was performed. A well-documented assessment should allow another qualified reviewer to understand what was known at the time, which evidence was considered, what uncertainty remained and why the conclusion was proportionate to the evidence.

This is consistent with the wider QPPV.com approach to pharmacovigilance governance: the useful unit of compliance is not an isolated document but a traceable chain connecting the requirement, the assessment, the decision, the evidence supporting it and the subsequent oversight.

Common Failure Modes in Biological-Product Pharmacovigilance

Several weaknesses can arise when the biological-product hierarchy is not reflected in operational systems. These should be understood as potential failure modes rather than as assertions that a particular organisation has experienced them.

Loss of product specificity

A safety report may be associated with an active substance or therapeutic class without retaining sufficient information about the actual medicinal product. This can make it difficult to distinguish products with the same or similar active substances and can weaken product-specific signal evaluation.

Incomplete batch information

Batch information may be absent from reports or may not be captured consistently. Not every adverse event requires a batch investigation, but loss of traceability removes information that may become important if a product- or batch-related hypothesis emerges.

Treating manufacturing information as purely a quality matter

A manufacturing change or quality investigation may be managed without considering whether the information has potential pharmacovigilance relevance. Conversely, pharmacovigilance may interpret a temporal association as evidence of a manufacturing problem without adequate quality and scientific assessment. Both approaches can lead to inappropriate conclusions.

Assuming a class effect without sufficient evidence

Related biological products can share mechanisms and safety characteristics, but similarity does not establish that a safety concern applies equally to every product in the class. The evidence should determine the level at which the concern is characterised.

Treating immunogenicity as a generic biological-class property

Immunogenicity is relevant across many biological products, but its clinical meaning depends on the individual product, disease, treatment context and immune response. A generic statement that a biological product is immunogenic is therefore insufficient for product-specific safety assessment.

These failure modes all arise from the same underlying problem: applying a classification level that is either too broad or too narrow for the question being assessed.

Inspection and Oversight Perspective

An inspection should not be approached as a test of whether an organisation can recite the biological-products guidance. The more meaningful question is whether the pharmacovigilance system can demonstrate that the characteristics of the biological product have been translated into effective controls.

An inspector could, for example, examine whether the organisation can identify the specific biological product associated with a case, whether batch information is captured and retrievable where relevant, whether manufacturing changes are communicated through appropriate interfaces, and whether safety assessments distinguish product-specific evidence from class-level assumptions. These are illustrative inspection questions, not claims about actual inspection findings.

Evidence should show both the existence of the control and its effectiveness. A written procedure stating that biological products are traceable is weaker evidence than a functioning system in which product and batch information can be retrieved, exceptions are identified, and the information is demonstrably available when a safety question requires it.

The same principle applies to cross-functional interfaces. An organisation may have procedures describing communication between pharmacovigilance and quality, but inspection evidence is stronger when actual investigations demonstrate that relevant information was exchanged, assessed and documented appropriately.

Practical Implementation

For an organisation introducing or reviewing its biological-product pharmacovigilance controls, the first step should be to map the biological products in scope against the level of specificity required for safety surveillance. The resulting product inventory should distinguish individual products sufficiently to support case processing, aggregate assessment, signal detection and traceability.

The next step is to identify where information about product characteristics, manufacturing changes, batches and related biological products is held. The organisation can then define the interfaces needed to make that information available to pharmacovigilance when relevant. This is more robust than attempting to place every piece of biological-product information inside the pharmacovigilance database itself.

Finally, the controls should be tested against realistic safety questions. For example: can the organisation determine which product was administered when two related products share an active substance name? Can it identify affected batches if a product-related concern emerges? Can pharmacovigilance obtain relevant information about a manufacturing change? Can an assessor distinguish evidence supporting a product-specific concern from evidence supporting a broader class hypothesis?

These questions test the operational value of the taxonomy. If the answers are consistently available and traceable, the classification framework has been translated into a functioning pharmacovigilance control system.

Relationship With the Wider Pharmacovigilance System

Biological-product pharmacovigilance does not constitute a separate pharmacovigilance system. The same core processes—individual case safety reporting, signal management, safety communication, risk management, periodic safety evaluation, quality management and regulatory interaction—continue to apply within the general EU pharmacovigilance framework.

The biological-specific considerations change the information and scientific context in which those processes operate. Product identity and batch traceability become particularly important; manufacturing and quality information may become relevant to safety assessment; immunogenicity may require specialised interpretation; and related products may need to be distinguished carefully when evaluating signals.

This relationship is important for the structure of the QPPV.com knowledge base. The biological-product series should deepen understanding of these product-specific considerations without reproducing the general articles that explain the underlying pharmacovigilance processes. The reader should be able to move from a biological-product article to the relevant general GVP topic and then return to the product-specific application.

Key Takeaways

Biological medicinal products are an umbrella regulatory category containing products with very different molecular, cellular, manufacturing and clinical characteristics. Their diversity means that no single classification axis is sufficient for pharmacovigilance.

A useful pharmacovigilance taxonomy therefore operates at several levels: biological medicinal product, product family or modality, subtype or technology, and individual medicinal product. Each level answers a different question and should be used only to the extent supported by the evidence.

The development and manufacture of a biological product are important to understanding its quality and safety context. Manufacturing changes are assessed through the applicable comparability framework, while pharmacovigilance provides continuing post-authorisation surveillance rather than replacing the comparability assessment. [8]

Immunogenicity and traceability are important cross-cutting considerations, but neither should be treated as a universal property with identical implications for every biological medicine. Product-specific scientific and regulatory context remains essential. [7]

The practical objective is not to create a separate pharmacovigilance system for biological medicines. It is to ensure that the general pharmacovigilance system contains sufficient product-specific information, scientific expertise, cross-functional interfaces and governance to detect and evaluate safety concerns at the appropriate level of specificity.

The next stage of the QPPV.com series can therefore move from this landscape framework to type-level articles. Those articles will examine the scientific characteristics, development history, mechanisms, clinical uses, safety considerations and pharmacovigilance implications of major biological product families without repeating the individual-product histories that will follow later.

References

1. European Medicines Agency. Guideline on good pharmacovigilance practices (GVP) — Product- or Population-Specific Considerations II: Biological medicinal products. EMA/579491/2012 Rev. 1. See the sections addressing immunogenicity and product traceability. [1]
2. European Parliament and Council. Directive 2001/83/EC on the Community code relating to medicinal products for human use, as amended. Annex I, Part I, including the definition of a biological medicinal product. [2]
3. European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues, and associated current EMA biosimilar guidance. [3]
4. European Parliament and Council. Regulation (EC) No 726/2004 laying down Community procedures for the authorisation, supervision and pharmacovigilance of medicinal products for human and veterinary use, as amended. [4]
5. European Parliament and Council. Regulation (EC) No 1394/2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004, as amended. [5]
6. European Medicines Agency. Good pharmacovigilance practices (GVP). Product- or population-specific considerations and the wider GVP framework. [6]
7. European Medicines Agency. Guideline on good pharmacovigilance practices (GVP) — Product- or Population-Specific Considerations II: Biological medicinal products. Current EMA guidance on biological-product pharmacovigilance, including immunogenicity and traceability. [7]
8. European Medicines Agency / ICH. ICH Q5E: Comparability of Biotechnological/Biological Products Subject to Changes in their Manufacturing Process. EMA scientific guideline, Step 5. [8]

Regulatory Note

This article distinguishes EU legislation from EMA guidance and operational interpretation. The definitions and legal requirements cited from Directive 2001/83/EC and Regulations (EC) No 726/2004 and No 1394/2007 are legally binding within their applicable scope. EMA GVP and scientific guidelines provide regulatory guidance and should not be presented as legislation. Operational controls described in this article are practical interpretations intended to support an effective pharmacovigilance system; they should be adapted to the applicable product, organisation, regulatory obligations and current guidance.

Regulatory and scientific guidance can be revised. The applicable current version of legislation, EMA guidance, product-specific regulatory documentation and relevant national requirements should therefore be verified when the article is used for an operational or regulatory decision.